Temedica, a Munich, Germany-based well being insights firm, raised €25M in Series B funding.
The spherical, which introduced whole funding raised to this point to €42m, was led by MIG Capital, in addition to a Munich-based household workplace.
The firm intends to make use of the funds to speed up growth of its ecosystem, which supplies holistic insights into the care realities and affected person journeys of thousands and thousands of sufferers by combining health-related information, and its growth efforts.
Led by CEO and Founder Gloria Seibert, Temedica is a well being insights firm whose mission is to allow personalised and individualized drugs, thereby specializing in sufferers and their particular person wants. The firm achieves this by linking health-related information from numerous sources, that are processed into insights in compliance with the GDPR.
From greater than 40 billion information factors on over 50,000 diagnoses, Temedica derives health-related insights on points comparable to illness development, therapy effectiveness, affected person journeys, and drugs adherence. The ecosystem brings collectively information from all kinds of sources, comparable to registry information, gross sales information of medically related merchandise, insurance coverage information, affected person expertise information, and – with express affected person consent – patient-generated information from affected person companion apps. The insights gained from the linked information provide tangible added worth to all stakeholders in the healthcare system: sufferers, well being care professionals, clinics, analysis establishments, pharmaceutical and biotechnology corporations, and pharmacies.